Full Press Release Details
INmune Bio, Inc. to Participate in the B.
Riley Fall 2021 Best Ideas in Oncology Series
Boca Raton, FL, Sept.
27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology company focused
on developing treatments that harness the patient's innate immune system to fight disease, today announced that Mark Lowdell, PhD,
Chief Scientific Officer and Chief Medical Officer, will be participating in an oncology panel at the B. Riley Fall 2021 Best Ideas in
Title: Improving Strategies to Harness
Date: Thursday, September 30, 2021
This event is open to institutional investors.
Interested parties may register for the panel here.
About INmune Bio, Inc.
INmune Bio, Inc. is a
publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system
to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively
neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed
for COVID-19 complications (Quellor ), cancer (INB03 ), Alzheimer's and Treatment Resistant Depression (Xpro ),
and NASH (LIVNate ). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's NK cells
to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine
approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation with components of the
innate immune system. To learn more, please visit www.inmunebio.com.
Information about Forward-Looking
Clinical trials are in
early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that
do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation
Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein
are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events
and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.
INB03 , Quellor , XPro1595, LIVNate , and INKmune are still in clinical trials or preparing to start clinical
trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved.
The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks
and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability of substantial additional
funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization;
and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission,
including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current
Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance
that may arise after the date of this release.